Risk assessment for Mycobacterium chimaera.
- Published in:
- Canada Communicable Disease Report, 2017, v. 43, n. 5, p. 119
- Publication type:
- Article
Works matching IS 11884169 AND DT 2017 AND VI 43 AND IP 5
Results: 8
1
2
Evaluation of latent tuberculosis infection surveillance in Peel region, Ontario, 2010-2014.
- Published in:
- Canada Communicable Disease Report, 2017, v. 43, n. 5, p. 114, doi. 10.14745/ccdr.v43i05a06
- By:
- Publication type:
- Article
3
Mycobacterium chimaera infections in post-operative patients exposed to heater-cooler devices: An overview.
- Published in:
- Canada Communicable Disease Report, 2017, v. 43, n. 5, p. 107, doi. 10.14745/ccdr.v43i05a05
- By:
- Publication type:
- Article
4
Bacteremia in children following introduction of conjugated pneumococcal vaccines.
- Published in:
- Canada Communicable Disease Report, 2017, v. 43, n. 5, p. 119
- By:
- Publication type:
- Article
5
Summary of the NACI Update on the Recommended Use of Hepatitis B Vaccine.
- Published in:
- Canada Communicable Disease Report, 2017, v. 43, n. 5, p. 104, doi. 10.14745/ccdr.v43i05a04
- By:
- Publication type:
- Article
6
Summary of the NACI Statement on Seasonal Influenza Vaccine for 2017-2018.
- Published in:
- Canada Communicable Disease Report, 2017, v. 43, n. 5, p. 96, doi. 10.14745/ccdr.v43i05a03
- By:
- Publication type:
- Article
7
Developing a vaccine for Haemophilus influenzae serotype a: Proceedings of a workshop.
- Published in:
- Canada Communicable Disease Report, 2017, v. 43, n. 5, p. 89, doi. 10.14745/ccdr.v43i05a02
- By:
- Publication type:
- Article
8
The emerging Haemophilus influenzae serotype a infection and a potential vaccine: Implementation science in action.
- Published in:
- Canada Communicable Disease Report, 2017, v. 43, n. 5, p. 85, doi. 10.14745/ccdr.v43i05a01
- By:
- Publication type:
- Article